{"id":"NCT00195013","sponsor":"Weill Medical College of Cornell University","briefTitle":"Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy","officialTitle":"A Randomized Placebo-controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients With a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-12","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2005-09-19","resultsPosted":"2017-08-18","lastUpdate":"2018-06-06"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Peripheral Neuropathy","Breast Cancer"],"interventions":[{"type":"DRUG","name":"glutamine","otherNames":["NutreStore"]},{"type":"DRUG","name":"Placebo","otherNames":["sugar pill"]}],"arms":[{"label":"Glutamine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Patients with breast cancer receiving paclitaxel chemotherapy who have mild symptoms of peripheral neuropathy will receive glutamine or placebo to try and improve symptoms.","primaryOutcome":{"measure":"Change in Peripheral Neuropathy Score","timeFrame":"Duration of study, approximately 10 weeks per subject","effectByArm":[{"arm":"Glutamine","deltaMin":0.3,"sd":null},{"arm":"Placebo","deltaMin":0.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":[]}}